Rankings / Cognitive

Atomoxetine

Cognitive · Selective NRI

Tier B

dopamineprescription
6.4 / 10
Tier B
Ev 8 Bn 5 Sf 5

Bottom line

Read Off Label grades Atomoxetine as B (6.4/10) based on strong evidence, med benefit magnitude, and a med-risk safety profile.

Full effect takes 4-8 weeks.

Studied, labeled, or reported-use context: 40-100 mg PO daily — Rx; not individualized guidance.

What the evidence says

Full effect takes 4-8 weeks. Moderate effect size in ADHD — smaller than stimulants on average. It is used when stimulants are contraindicated or when anxiety or substance-use risk affects treatment selection. Not a DEA-scheduled drug.

Mechanism

Selective norepinephrine reuptake inhibitor; also increases PFC dopamine (NET clears DA in frontal cortex); non-stimulant; no abuse potential

Studied, labeled, or reported dose & route

40-100 mg PO daily

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Atomoxetine's effects?
Read Off Label rates the evidence for Atomoxetine as Strong and the benefit magnitude as med, producing an overall grade of B (6.4/10). Full effect takes 4-8 weeks.
What safety findings are reported for Atomoxetine?
Atomoxetine has a med risk profile in the database. Med (hepatotoxicity warning, cardiovascular effects, suicidal ideation in youth) Legal status: Rx.
What doses or routes are reported for Atomoxetine?
40-100 mg PO daily This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Atomoxetine work?
Selective norepinephrine reuptake inhibitor; also increases PFC dopamine (NET clears DA in frontal cortex); non-stimulant; no abuse potential

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.